In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), with a price target of $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oliver McCammon has given his Buy rating due to a combination of factors including Aura Biosciences’ recent advancements and strategic initiatives. The company has made significant progress by enrolling the first patient in the multi-dose Phase 1b/2 trial of bel-sar for non-muscle invasive bladder cancer, which marks a critical step in their clinical development pipeline.
Additionally, Aura is actively progressing with the Phase 3 CoMpass trial for early-stage choroidal melanoma, with a robust enrollment strategy that is on track to meet its targets. The expansion of their ocular oncology pipeline, particularly with the ongoing Phase 2 trial for metastases to the choroid, highlights the company’s potential to establish a strong presence in the ocular oncology market. These developments, coupled with strategic leadership appointments and patent filings, underpin McCammon’s positive outlook on Aura’s growth prospects.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $23.00 price target.